Ascentage Pharma Group International - American Depository Shares

Aug 13, 2026

Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit

Ascentage Pharma will participate in the Evercore 2nd Annual China Biotech Summit from August 17-19, 2026. The company's management will engage in a fireside chat and one-on-one investor meetings during the event. Ascentage Pharma is recognized for its innovative therapies targeting cancer, including its approved products and ongoing clinical trials.

Aug 5, 2026

Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

Ascentage Pharma Group International will announce its six-month interim results for 2026 on August 19, 2026. The company will host investor webcasts in both Mandarin and English to discuss these results and provide business updates. Ascentage Pharma is recognized for its innovative cancer therapies and has multiple ongoing Phase III trials.

Jul 26, 2026

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

Ascentage Pharma's Chairman and CEO, Dr. Dajun Yang, has been named No. 3 in The Medicine Maker Power List 2026 for his contributions to oncology and drug development. The recognition highlights his leadership in advancing innovative cancer therapies, including olverembatinib and lisaftoclax. Ascentage Pharma continues to progress with multiple global Phase III trials, addressing significant unmet medical needs in cancer treatment.

Jun 14, 2026

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

Ascentage Pharma presented 17 clinical updates at the EHA2026 Congress, showcasing the efficacy of olverembatinib and lisaftoclax in treating hematologic malignancies. Olverembatinib demonstrated significant responses in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Lisaftoclax showed promising results in pediatric patients with relapsed/refractory conditions. These findings support the ongoing development of these therapies.

Jun 12, 2026

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly d

Ascentage Pharma Group International announced a voluntary share purchase by the Trustee for the 2022 RSU Scheme. On June 11, 2026, the Trustee acquired 110,000 existing shares for a total consideration of HK$3,671,094, representing approximately 0.0294% of the total issued shares. This purchase aims to fulfill the company's obligations related to the RSUs upon their vesting. No new grants have been made under the RSU Scheme aside from initial awards since June 2022, indicating a steady approach to equity compensation.

May 31, 2026

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

Ascentage Pharma presented its first dataset on alrizomadlin (APG-115), an MDM2-p53 inhibitor, at the 2026 ASCO Annual Meeting. The data showed promising antitumor activity in pediatric patients with relapsed/metastatic rhabdomyosarcoma and other soft-tissue sarcomas. Alrizomadlin demonstrated a favorable safety profile and was included in China's SPARK Plan for further development in pediatric oncology.

May 31, 2026

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

Ascentage Pharma presented promising data on olverembatinib combined with blinatumomab at the 2026 ASCO Annual Meeting. The Phase Ib study showed high response rates in patients with relapsed/refractory Ph+ BCP-ALL and CML-LBP. The combination therapy was well tolerated, indicating its potential as a novel treatment strategy for these challenging hematologic malignancies.

May 31, 2026

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

Ascentage Pharma presented updated clinical data for olverembatinib as a second-line therapy for chronic-phase chronic myeloid leukemia (CML-CP) at the 2026 ASCO Annual Meeting. The study reported a complete cytogenetic response rate of 91.3% and a major molecular response rate of 60.9% after 24 cycles of treatment. The drug demonstrated a manageable safety profile, with no new safety signals identified, reinforcing its potential in treating patients who failed first-line therapy.

May 22, 2026

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

Ascentage Pharma announced the presentation of six abstracts at the 2026 ASCO Annual Meeting, showcasing data from ongoing studies of its lead drug candidates. Notably, olverembatinib demonstrated high response rates in patients with chronic myeloid leukemia and other hematological malignancies. The meeting will occur from May 29 to June 2, 2026, in Chicago, IL.

May 13, 2026

Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress

Ascentage Pharma announced that it will present 17 clinical advances at the upcoming EHA2026 Congress in Stockholm, Sweden. The presentations will include key data on Olverembatinib and Lisaftoclax, two innovative therapies for hematologic malignancies. This event is a major platform for sharing research advancements in hematology.

May 12, 2026

Ascentage Pharma to Participate in Three Upcoming Investor Conferences ROCKVILLE, MD. and

Ascentage Pharma Group International announced its participation in three upcoming investor conferences, indicating active engagement with investors. The company continues to focus on developing novel therapies for unmet medical needs in oncology, notably through its robust pipeline which includes approved drugs and ongoing Phase III trials. Ascentage Pharma leverages strategic partnerships with major biotech and pharmaceutical firms to enhance its research and development efforts.

May 1, 2026

Hong Kong Exchanges and Clearing

Ascentage Pharma Group International has announced its Annual General Meeting (AGM) to take place on May 20, 2026, at its facility in Suzhou, Jiangsu, China. The notice includes details about resolutions related to share allotments and repurchases, which will require the approval of shareholders. The notice underscores the company's compliance with regulations and procedures regarding shareholder meetings and mandates. The Board of Directors is led by Dr. Yang Dajun, with various members listed in the announcement.

Apr 22, 2026

Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026

Ascentage Pharma announced the selection of six abstracts for presentation at the 2026 ASCO Annual Meeting, including three rapid oral presentations. The data will focus on their key drug candidates: Olverembatinib, Lisaftoclax, and Alrizomadlin. This marks the company's ninth consecutive year at ASCO, emphasizing its commitment to advancing cancer therapies.

Apr 20, 2026

Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting

Ascentage Pharma announced the presentation of four preclinical studies at the AACR 2026 Annual Meeting, showcasing the potential of their drug candidates, including Olverembatinib, APG-2449, and APG-5918. These studies explore innovative combination therapies for various cancers, indicating the company's commitment to addressing unmet medical needs. The research highlights new applications and strategic focuses in cancer treatment.

Mar 26, 2026

Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates

Ascentage Pharma reported its unaudited financial results for 2025, highlighting a revenue decrease to US$82.1 million, primarily due to a lack of intellectual property revenue. Despite this, product sales for Olverembatinib surged by 80.6%, and the company successfully launched Lisaftoclax, which is gaining traction in the market. The company continues to advance its late-stage clinical programs, including three Phase III trials for Olverembatinib and ongoing studies for Lisaftoclax.

Mar 18, 2026

Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026

Ascentage Pharma will present four abstracts at the AACR Annual Meeting 2026, showcasing preclinical results from its innovative pipeline. The data highlights the efficacy of three drug candidates: Olverembatinib, APG-2449, and APG-5918, in various cancer models. This event emphasizes advancements in cancer research and therapy development.

Feb 23, 2026

Ascentage Pharma to Participate in Three Upcoming Investor Conferences

Ascentage Pharma is set to participate in three upcoming investor conferences, showcasing its commitment to transparency and investor engagement. The company has a robust pipeline, including approved therapies like Olverembatinib and Lisaftoclax, targeting unmet medical needs in cancer. These activities highlight Ascentage's strategic focus on innovation and collaboration in the biopharmaceutical sector.

Feb 9, 2026

Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Ascentage Pharma will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026. The company's management is scheduled for a fireside chat on February 12th. Ascentage is known for its innovative therapies in cancer treatment, including Olverembatinib and Lisaftoclax, both of which have received regulatory approvals.

Feb 6, 2026

Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288

Ascentage Pharma has announced that its BTK-targeted protein degrader, APG-3288, has received IND clearance from the China CDE, following similar clearance from the U.S. FDA. This marks a significant milestone in the drug's development for treating relapsed/refractory hematologic malignancies. The upcoming Phase I study will assess its safety, tolerability, and efficacy. APG-3288 utilizes a novel mechanism to address treatment resistance seen with conventional BTK inhibitors.

Jan 16, 2026

Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference

Ascentage Pharma presented its global innovation strategy at the 44th Annual J.P. Morgan Healthcare Conference, highlighting achievements from 2025 and outlining plans for 2026. The company emphasized its dual-engine growth strategy driven by core products Olverembatinib and Lisaftoclax. Additionally, FDA clearance for the BTK degrader APG-3288 marks a significant step in expanding its innovative pipeline.

Jan 14, 2026

Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44 th Annual J.P. Morgan Healthcare Conference Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine gro

Ascentage Pharma presented its global innovation strategy at the 44th Annual J.P. Morgan Healthcare Conference, highlighting significant achievements in 2025 and outlining plans for 2026. The company reported dual-engine growth driven by its hematology products, Olverembatinib and Lisaftoclax, which have shown promising clinical data. Additionally, the recent FDA clearance for APG-3288, a next-generation BTK degrader, facilitates the company's expansion in targeted therapies. Ascentage Pharma aims to continue advancing its global clinical trials and commercialization efforts, setting a strong foundation for sustained growth in the oncology sector.

Jan 6, 2026

AAPGFDA Updates

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigation

Ascentage Pharma announced that its novel BTK-targeted protein degrader, APG-3288, has received Investigational New Drug (IND) clearance from the U.S. FDA. This clearance allows the company to initiate a global Phase I study evaluating APG-3288 in patients with relapsed or refractory B-cell malignancies. APG-3288 aims to offer a distinct treatment mechanism by inducing degradation of the BTK protein, potentially overcoming resistance associated with conventional BTK inhibitors. The clearance signifies a strategic milestone for Ascentage Pharma as it expands its clinical development efforts in hematologic malignancies.

Dec 18, 2025

Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference

Ascentage Pharma Group International will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company focuses on developing therapies for cancer and has a robust pipeline, including Olverembatinib and Lisaftoclax. These products have received regulatory approvals in China and are involved in multiple global Phase III trials.

Dec 17, 2025

Ascentage Pharma to Present at 44 th Annual J.P. Morgan Healthcare Conference ROCKVILLE, MD. and

Ascentage Pharma Group International will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company is recognized for its innovative cancer therapies and has a strong pipeline, including FDA-cleared global Phase III trials for its products Olverembatinib and Lisaftoclax. Ascentage Pharma has established valuable partnerships with top pharmaceutical companies and academic institutions, enhancing its research and development capabilities. The presentation underscores the company's commitment to addressing unmet medical needs in oncology.

Dec 8, 2025

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

Ascentage Pharma presented pivotal data on Lisaftoclax at the 2025 ASH Annual Meeting, demonstrating its efficacy as a monotherapy for patients with relapsed/refractory CLL/SLL who failed prior BTK inhibitors. The study showed a 62.5% objective response rate and a manageable safety profile, supporting its recent NDA approval in China. The results underscore the drug's potential to address significant unmet clinical needs in this patient population.

Dec 8, 2025

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

Ascentage Pharma presented encouraging data from a Phase Ib/II study of Lisaftoclax at the ASH Annual Meeting. The study demonstrated the drug's potential in treating myeloid malignancies, particularly in patients previously exposed to venetoclax. The results highlighted the drug's efficacy and tolerability, suggesting it could be a valuable treatment option for these patients.

Dec 8, 2025

ASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment 76.7% complete cytogenetic response rate achieved in patients who failed second-g

Ascentage Pharma presented updated data on Olverembatinib at the 67th ASH Annual Meeting, highlighting its efficacy in second-line treatment for chronic myeloid leukemia (CML-CP). The drug showed a complete cytogenetic response rate of 76.7% in patients who previously failed other therapies. Safety results were consistent with prior data, with no new safety signals reported. Ascentage Pharma aims to accelerate clinical programs following these encouraging findings, which support Olverembatinib's therapeutic potential.

Dec 6, 2025

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting Lisaftoclax monotherapy demonstrated significant and durable cl

Ascentage Pharma has presented pivotal data for Lisaftoclax at the 2025 ASH Annual Meeting, showcasing its effectiveness as a monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The Phase II study results indicated a 62.5% objective response rate among heavily pretreated patients, including those with high-risk genetic factors. Additionally, no instances of tumor-lysis syndrome were reported, suggesting a favorable safety profile. This data supports the drug's recent NDA approval by China's NMPA.

Dec 4, 2025

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA ROCKVILLE, Md. and

Ascentage Pharma has received clearance from the US FDA and the EMA to conduct a global Phase III study of olverembatinib for treating newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This marks the second global Phase III study cleared for olverembatinib, which aims to evaluate its efficacy and safety in combination with chemotherapy. The POLARIS-1 study is notably designed to enroll patients across multiple countries, potentially accelerating the drug's registration process. Initial results expected at the upcoming ASH 2025 meeting highlight its promising efficacy rates compared to existing treatments.

Dec 1, 2025

Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025 ROCKVILLE, MD. and

Ascentage Pharma announced it will host an investor webcast on December 11, 2025, to discuss key data from the upcoming ASH Annual Meeting. The webcast will feature updates from CEO Dr. Dajun Yang and the management team focusing on the company's innovative pipeline. Ascentage has a strong portfolio of therapies aimed at addressing unmet medical needs in cancer, including notable products like Olverembatinib and Lisaftoclax, and has secured partnerships with major biopharmaceutical firms.

Nov 24, 2025

Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature's Signal Transduction and Targeted Therapy Largest prospective clin

Ascentage Pharma announced the publication of promising Phase Ib trial data for olverembatinib in gastrointestinal stromal tumors (GIST), specifically for SDH-deficient cases. The study reported a 23.1% objective response rate and established a new therapeutic mechanism targeting lipid metabolism. This represents the largest prospective clinical trial in this rare tumor subtype, highlighting olverembatinib's potential as a novel treatment option. The findings are significant given the current lack of effective therapies for patients with SDH-deficient GIST.

Nov 19, 2025

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025 ROCKVILLE, MD. and

Ascentage Pharma Group International, a biopharmaceutical company, announced its participation in three investor conferences scheduled for December 2025. The company specializes in developing novel therapies for cancer and has established a strong portfolio, including approved products like Olverembatinib and Lisaftoclax. These events highlight Ascentage's commitment to engaging with the investment community amidst its ongoing clinical trials and partnerships in the industry.

Nov 4, 2025

Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025

Ascentage Pharma announced that multiple studies on its drug olverembatinib will be presented at the 67th ASH Annual Meeting. This includes the first dataset from the POLARIS-1 Phase III study, which evaluates olverembatinib combined with low-intensity chemotherapy for newly diagnosed Ph+ ALL. The meeting will take place from December 6-9, 2025, in Orlando, Florida.

Nov 4, 2025

Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025

Ascentage Pharma announced that data from two clinical studies of its Bcl-2 inhibitor, lisaftoclax, will be presented at the ASH 2025 Annual Meeting. The presentations include an oral report on a Phase II study for relapsed/refractory CLL/SLL and a poster on its combination with azacitidine for myeloid malignancies. This marks the fourth consecutive year that lisaftoclax data has been featured at ASH.

Oct 30, 2025

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025

Ascentage Pharma is set to participate in two investor conferences in November 2025. The company is recognized for its innovative therapies targeting cancer, including its approved products Olverembatinib and Lisaftoclax. Ascentage is also conducting several Phase III trials for its therapies, showcasing its commitment to addressing unmet medical needs in oncology.

Oct 7, 2025

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025 ROCKVILLE, MD. and

Ascentage Pharma Group International (NASDAQ: AAPG) announced its participation in three upcoming investor conferences in October 2025. The company, known for its focus on developing novel cancer therapies, has showcased a robust pipeline of products, including its approved therapies for chronic myelogenous leukemia and various hematologic cancers. Ascentage's strategic engagements and collaborations with notable industry players highlight its commitment to advancing cancer treatment solutions.

Aug 25, 2025

▼ -9.2%on this news

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025 ROCKVILLE, Md. and

Ascentage Pharma Group International (NASDAQ: AAPG) announced its participation in three upcoming investor conferences scheduled for September 2025. The company's management will engage with investors to discuss their innovative drug pipeline and recent product approvals, including Olverembatinib and Lisaftoclax. These therapeutic advancements aim to address unmet medical needs in cancer treatments. The events reflect Ascentage's commitment to transparent investor relations and the ongoing development of its products in the biopharmaceutical sector.

Aug 20, 2025

Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates

Ascentage Pharma reported its interim financial results for the first half of 2025, showing a significant increase in Olverembatinib sales and the historic approval of Lisaftoclax for CLL/SLL treatment. Despite a decrease in overall revenue and a reported loss, the company is actively advancing nine registrational clinical trials. The successful financing of US$190.1 million enhances its capabilities for commercialization and development.

Aug 17, 2025

▲ +5.5%on this newsshared move

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

Ascentage Pharma has received clearance from the FDA and EMA to conduct the GLORA-4 Phase III study of lisaftoclax, a Bcl-2 inhibitor, for treating higher-risk myelodysplastic syndrome (HR-MDS). This study aims to evaluate the drug's efficacy in combination with azacitidine. If successful, it could fill a significant treatment gap in HR-MDS, marking a major advancement in therapy options.

Aug 1, 2025

Ascentage Pharma to Participate in Evercore China Biotech Summit

Ascentage Pharma will participate in the Evercore China Biotech Summit from August 19-21, 2025, in Shanghai. The company's management will engage in a fireside chat and one-on-one meetings with investors. Ascentage Pharma is known for its innovative cancer therapies, including lead assets olverembatinib and lisaftoclax, which have received regulatory approvals in China.

Jul 23, 2025

Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025

Ascentage Pharma will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. The management will engage in one-on-one meetings with investors during the event. The company is known for its innovative cancer therapies and has several global Phase III trials underway for its lead assets, olverembatinib and lisaftoclax.

Jul 14, 2025

▼ -5.3%on this newsshared move

Ascentage Pharma Announces Pricing of Top-Up Placement ROCKVILLE, Md. and

Ascentage Pharma Group International announced the pricing of a top-up placement of 22 million ordinary shares at HKD68.60 each, expected to generate approximately US$192.3 million in gross proceeds. The oversubscribed placement, managed by an affiliate of CEO Dajun Yang, will be used to bolster commercialization, global clinical development, and operational capacities. The transaction is set to close on July 17, 2025, pending standard conditions, although the shares will not be registered under U.S. securities laws.

Jun 15, 2025

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL ROCKVILLE, Md. and

Ascentage Pharma presented data on olverembatinib at the EHA 2025 Annual Congress, highlighting its efficacy for treating Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The studies reported high complete remission and molecular response rates, alongside favorable tolerability in patients. Additionally, various combination therapies involving olverembatinib have shown potential in enhancing treatment options and long-term prognoses for patients with Ph+ ALL. A preclinical study of another asset, APG-5918, demonstrated potent antitumor activity in T-cell lymphoma.

Jun 9, 2025

▲ +5.3%on this news

Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress ROCKVILLE, Md. and

Ascentage Pharma announced the selection of thirteen studies concerning its key assets, including olverembatinib and lisaftoclax, for presentation at the 2025 European Hematology Association Annual Congress in Milan. The congress, attended by over 10,000 participants from more than 100 countries, will showcase innovative research in hematology. Ascentage's studies focus on various treatments and combinations involving their drugs, underlining their commitment to addressing unmet medical needs in oncology. The company is actively engaged in significant clinical trials, enhancing its visibility and credibility in the field.

Jun 2, 2025

Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors ROCKVILLE, Md. and

Ascentage Pharma has announced promising clinical data for alrizomadlin in a Phase II study targeting advanced adenoid cystic carcinoma and other solid tumors, presented at the ASCO 2025 Annual Meeting. The MDM2-p53 inhibitor showed significant antitumor activity both as a monotherapy and in combination with the PD-1 inhibitor toripalimab, with notable objectives rates and well-tolerated side effects. This positions alrizomadlin as a viable new treatment option for patients with limited therapeutic alternatives, particularly in rare cancers. Ascentage Pharma continues to focus on meeting unmet medical needs globally.

May 22, 2025

Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 ROCKVILLE, Md. and

Ascentage Pharma announced that new clinical data for its Bcl-2 inhibitor, lisaftoclax, will be featured in an oral presentation at the ASCO 2025 Annual Meeting. The Phase 1b/2 study showed that lisaftoclax, in combination with azacitidine, demonstrated significant antitumor activity in patients with treatment-naïve and venetoclax-refractory myeloid malignancies. Alongside, data on alrizomadlin for solid tumors will also be presented, both drug candidates being crucial to Ascentage's cancer treatment pipeline. The studies support their ongoing development in addressing unmet medical needs in oncology.

Apr 28, 2025

Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax R

Ascentage Pharma announced the presentation of results from five preclinical studies at the 2025 AACR Annual Meeting. The studies, highlighting the synergistic effects of olverembatinib combined with lisaftoclax, show promise in preclinical models for acute myeloid leukemia and T-cell acute lymphoblastic leukemia. This data adds to the company's commitment to advancing the clinical development of its innovative therapies targeting critical cancers. Ascentage plans to continue its efforts in bringing more treatment options to patients in need.

Apr 23, 2025

▲ +10.6%on this newsshared move

Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin ROCKVILLE, Md. and

Ascentage Pharma announced that it will present data from two clinical studies at the upcoming 2025 ASCO Annual Meeting. The studies include updates on its key drug candidates, lisaftoclax and alrizomadlin, which focus on hematological malignancies and solid tumors. The presentations will feature findings from a Phase Ib/II study of a combination regimen involving lisaftoclax and azacitidine, as well as a Phase 2 study of alrizomadlin in advanced adenoid cystic carcinoma. This participation underscores the company's commitment to advancing innovative therapies for unmet medical needs.

Apr 17, 2025

Pelcitoclax ( APG - 1252 ) APG - 2449 APG - 5918 Lisaftoclax ( APG - 2575 ) Alrizomadlin ( APG - 115 ) (Incorporated in the Cayman Islands with limited liability) Stock Code: HKEX: 6855 NASDAQ: AAPG Ascentage Pharma Grou

Ascentage Pharma Group International has released its annual report for 2024, detailing various company activities and financial information. The report includes definitions of key terms relevant to the company's operations, including various drug candidates such as Pelcitoclax and Lisaftoclax, and their intended mechanisms. Key financial highlights and governance structures are also covered, offering insights into the company's financial performance and strategic direction. This comprehensive view aims to inform stakeholders about the company's current state and future outlook.

Mar 27, 2025

▲ +10%on this news· ran to +25% by day 3shared move

ASCENTAGE PHARMA REPORTS FULL YEAR 2024 UNAUDITED FINANCIAL RESULTS AND BUSINESS UPDATES Revenue in 2024 increased 342% year-over-year to US$134.3 million (RMB980.7 million), attributable in part to Takeda's option payme

Ascentage Pharma reported a remarkable financial increase for 2024, with revenue rising 342% to US$134.3 million, driven by significant sales of olverembatinib and a US$100 million payment from Takeda. The commercialization of olverembatinib is now notably endorsed under China's National Reimbursement Drug List, enhancing patient access. Additional advancements include the acceptance of the NDA for lisaftoclax by China's CDE with Priority Review designation. However, the company still experienced a loss of US$55.6 million for the year, although this was a considerable improvement from the previous year's loss.

Mar 25, 2025